BEIJING, March 4 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced it will present at the Rodman & Renshaw Annual China Investment Conference being held March 7-9 in Beijing, China. Presentation details are noted below.
Date: March 9, 2010
Time: 3:40 pm Beijing Time
Location: Ballroom IIi, The Regent Hotel, Beijing China
Presenter: Dr. Guoqing Jiang, Chairman and CEO
Joined by: Mr. Allen Tang, Assistant to the CEO
Conference participation is by invitation and registration is mandatory. For more information on the conference, or to book a one-on-one meeting, contact your Rodman & Renshaw representative or visit http://www.rodm.com .
About Rodman & Renshaw (NasdaqGM: RODM)
Rodman & Renshaw Capital Group, Inc., (NasdaqGM: RODM) offers corporate finance services focusing on various public and private equity products, which include private investment in public equity, registered direct offerings, private placements, and public offerings, as well as provides Collateralized Acquisition Pool, a product used to facilitate a targeted acquisition. The company also involves in strategic advisory services, which include identifying and/or evaluating acquisition targets or acquirers; providing valuation analyses; evaluating and proposing financial and strategic alternatives; rendering fairness opinions; advising on timing, structure, and pricing of transaction; assisting in negotiating and closing a transaction; advising on the sale process; and assisting in preparing a memorandum or other sales materials. In addition, it provides merchant banking and asset management services. Rodman & Renshaw Capital Group serves public and private biotechnology companies. The company is headquartered in New York, New York.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. Tianyin currently has 48 SFDA approved products, 41 which are manufactured and marketed. 23 of these products are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has also maintains a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 730 salespeople. The Company is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press release or upcoming conference presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact:
For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
Tel: +86-158-2122-5642
Email: Allen.y.tang@gmail.com
Investors:
Mr. Matthew Hayden, HC International
Tel: +1-561-245-5155
Email: matt.hayden@hcinternational.net
Web: http://www.hcinternational.net